These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16300476)

  • 41. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.
    Souness JE; Aldous D; Sargent C
    Immunopharmacology; 2000 May; 47(2-3):127-62. PubMed ID: 10878287
    [No Abstract]   [Full Text] [Related]  

  • 42. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.
    Houslay MD; Adams DR
    Biochem J; 2003 Feb; 370(Pt 1):1-18. PubMed ID: 12444918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
    Smith VB; Spina D
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans.
    Bian H; Zhang J; Wu P; Varty LA; Jia Y; Mayhood T; Hey JA; Wang P
    Biochem Pharmacol; 2004 Dec; 68(11):2229-36. PubMed ID: 15498513
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
    Muise ES; Chute IC; Claveau D; Masson P; Boulet L; Tkalec L; Pon DJ; Girard Y; Frenette R; Mancini JA
    Biochem Pharmacol; 2002 Apr; 63(8):1527-35. PubMed ID: 11996895
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.
    Huang Z; Mancini JA
    Curr Med Chem; 2006; 13(27):3253-62. PubMed ID: 17168849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the utero-relaxant effect of PDE4-selective inhibitors.
    Méhats C; Tanguy G; Paris B; Robert B; Pernin N; Ferré F; Leroy MJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):817-23. PubMed ID: 10640323
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vivo selective binding of (R)-[11C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues.
    Kenk M; Greene M; Thackeray J; deKemp RA; Lortie M; Thorn S; Beanlands RS; DaSilva JN
    Nucl Med Biol; 2007 Jan; 34(1):71-7. PubMed ID: 17210463
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.
    Ducharme Y; Friesen RW; Blouin M; Côté B; Dubé D; Ethier D; Frenette R; Laliberté F; Mancini JA; Masson P; Styhler A; Young RN; Girard Y
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1923-6. PubMed ID: 12749899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).
    Barnette MS
    Prog Drug Res; 1999; 53():193-229. PubMed ID: 10616299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Conformational difference between PDE4 apoenzyme and holoenzyme.
    Laliberté F; Han Y; Govindarajan A; Giroux A; Liu S; Bobechko B; Lario P; Bartlett A; Gorseth E; Gresser M; Huang Z
    Biochemistry; 2000 May; 39(21):6449-58. PubMed ID: 10828959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of (R)- and (S)-isomer of 7-methyl- or 8-alkyl-4,5,7,8-tetrahydroimidazo[2,1-i]- purin-5-one.
    Suzuki H; Nomura M; Miyamoto K; Sawanishi H; Yamamoto K
    Biol Pharm Bull; 2004 Mar; 27(3):357-60. PubMed ID: 14993802
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).
    Thompson WJ; Ashikaga T; Kelly JJ; Liu L; Zhu B; Vemavarapu L; Strada SJ
    Biochem Pharmacol; 2002 Feb; 63(4):797-807. PubMed ID: 11992650
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process.
    Terry R; Cheung YF; Praestegaard M; Baillie GS; Huston E; Gall I; Adams DR; Houslay MD
    Cell Signal; 2003 Oct; 15(10):955-71. PubMed ID: 12873709
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New orally active PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
    Bioorg Med Chem; 2004 Aug; 12(15):4089-100. PubMed ID: 15246087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity.
    Heystek HC; Thierry AC; Soulard P; Moulon C
    Int Immunol; 2003 Jul; 15(7):827-35. PubMed ID: 12807821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions.
    Houslay MD; Sullivan M; Bolger GB
    Adv Pharmacol; 1998; 44():225-342. PubMed ID: 9547887
    [No Abstract]   [Full Text] [Related]  

  • 58. Thalidomide analogs and PDE4 inhibition.
    Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen Y; Stirling DI
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2669-74. PubMed ID: 9873600
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
    Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Fattori R; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2002 Jan; 12(1):5-8. PubMed ID: 11738561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.